Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-β-1-integrin complex formation

Y. Liu, E. Kyle, R. Lieberman, J. Crowell, G. Kelloff, Raymond Bergan

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

It has previously been shown that changes in the activity of focal adhesion kinase (FAK), and its binding to β-1-integrin, accompany genistein-induced adhesion of prostate cells. Consumption of genistein world wide is associated with a lower incidence of metastatic prostate cancer. Early human clinical trials of genistein are under way to evaluate genistein's potential causal role in this regard. Though an important cell adhesion-associated signaling molecule, FAK's role in regulating prostate cell adhesion was not clear. Elucidation of this process would provide important information relating to both biology and potential clinical endpoints. It was hypothesized that FAK activation and complex formation are temporally related in prostate cells, and can thus be separated. Significant activation of FAK was demonstrated when cells adhered to fibronectin, as compared to poly-L-lysine, thus demonstrating that β-1-integrin plays a significant role in activating FAK. Neither FAK activation, nor FAK-integrin complex formation, required β-1-integrin ligand. However, disruption of the cellular cytoskeleton by cytochalasin D prevented FAK activation, but did not block genistein-induced complex formation. In the face of a disrupted cytoskeleton, signaling through FAK could not be restored through either integrin cross linking, or re-establishment of tensile forces via attachment to solid matrix. These studies demonstrate that FAK-β-1-integrin complex formation does not require FAK activation, suggesting that it is an early event in prostate cell adhesion. An intact cytoskeleton is necessary for FAK activation. The functional importance of β-1-integrin in prostate cells is demonstrated. Current findings support plans to test genistein in prostate cancer.

Original languageEnglish (US)
Pages (from-to)203-212
Number of pages10
JournalClinical and Experimental Metastasis
Volume18
Issue number3
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Focal Adhesion Kinase 1
Focal Adhesion Protein-Tyrosine Kinases
Genistein
Integrins
Phosphorylation
Prostate
Cell Adhesion
Cytoskeleton
Prostatic Neoplasms
Cytochalasin D
Fibronectins
Lysine

Keywords

  • Cell adhesion
  • Focal adhesion kinase
  • Genistein
  • Integrin
  • Prostate cancer
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research

Cite this

Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-β-1-integrin complex formation. / Liu, Y.; Kyle, E.; Lieberman, R.; Crowell, J.; Kelloff, G.; Bergan, Raymond.

In: Clinical and Experimental Metastasis, Vol. 18, No. 3, 2000, p. 203-212.

Research output: Contribution to journalArticle

@article{e6b42c2f52ab469dae2e0a603c6bca05,
title = "Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-β-1-integrin complex formation",
abstract = "It has previously been shown that changes in the activity of focal adhesion kinase (FAK), and its binding to β-1-integrin, accompany genistein-induced adhesion of prostate cells. Consumption of genistein world wide is associated with a lower incidence of metastatic prostate cancer. Early human clinical trials of genistein are under way to evaluate genistein's potential causal role in this regard. Though an important cell adhesion-associated signaling molecule, FAK's role in regulating prostate cell adhesion was not clear. Elucidation of this process would provide important information relating to both biology and potential clinical endpoints. It was hypothesized that FAK activation and complex formation are temporally related in prostate cells, and can thus be separated. Significant activation of FAK was demonstrated when cells adhered to fibronectin, as compared to poly-L-lysine, thus demonstrating that β-1-integrin plays a significant role in activating FAK. Neither FAK activation, nor FAK-integrin complex formation, required β-1-integrin ligand. However, disruption of the cellular cytoskeleton by cytochalasin D prevented FAK activation, but did not block genistein-induced complex formation. In the face of a disrupted cytoskeleton, signaling through FAK could not be restored through either integrin cross linking, or re-establishment of tensile forces via attachment to solid matrix. These studies demonstrate that FAK-β-1-integrin complex formation does not require FAK activation, suggesting that it is an early event in prostate cell adhesion. An intact cytoskeleton is necessary for FAK activation. The functional importance of β-1-integrin in prostate cells is demonstrated. Current findings support plans to test genistein in prostate cancer.",
keywords = "Cell adhesion, Focal adhesion kinase, Genistein, Integrin, Prostate cancer, Tyrosine kinase inhibitor",
author = "Y. Liu and E. Kyle and R. Lieberman and J. Crowell and G. Kelloff and Raymond Bergan",
year = "2000",
doi = "10.1023/A:1006729106034",
language = "English (US)",
volume = "18",
pages = "203--212",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-β-1-integrin complex formation

AU - Liu, Y.

AU - Kyle, E.

AU - Lieberman, R.

AU - Crowell, J.

AU - Kelloff, G.

AU - Bergan, Raymond

PY - 2000

Y1 - 2000

N2 - It has previously been shown that changes in the activity of focal adhesion kinase (FAK), and its binding to β-1-integrin, accompany genistein-induced adhesion of prostate cells. Consumption of genistein world wide is associated with a lower incidence of metastatic prostate cancer. Early human clinical trials of genistein are under way to evaluate genistein's potential causal role in this regard. Though an important cell adhesion-associated signaling molecule, FAK's role in regulating prostate cell adhesion was not clear. Elucidation of this process would provide important information relating to both biology and potential clinical endpoints. It was hypothesized that FAK activation and complex formation are temporally related in prostate cells, and can thus be separated. Significant activation of FAK was demonstrated when cells adhered to fibronectin, as compared to poly-L-lysine, thus demonstrating that β-1-integrin plays a significant role in activating FAK. Neither FAK activation, nor FAK-integrin complex formation, required β-1-integrin ligand. However, disruption of the cellular cytoskeleton by cytochalasin D prevented FAK activation, but did not block genistein-induced complex formation. In the face of a disrupted cytoskeleton, signaling through FAK could not be restored through either integrin cross linking, or re-establishment of tensile forces via attachment to solid matrix. These studies demonstrate that FAK-β-1-integrin complex formation does not require FAK activation, suggesting that it is an early event in prostate cell adhesion. An intact cytoskeleton is necessary for FAK activation. The functional importance of β-1-integrin in prostate cells is demonstrated. Current findings support plans to test genistein in prostate cancer.

AB - It has previously been shown that changes in the activity of focal adhesion kinase (FAK), and its binding to β-1-integrin, accompany genistein-induced adhesion of prostate cells. Consumption of genistein world wide is associated with a lower incidence of metastatic prostate cancer. Early human clinical trials of genistein are under way to evaluate genistein's potential causal role in this regard. Though an important cell adhesion-associated signaling molecule, FAK's role in regulating prostate cell adhesion was not clear. Elucidation of this process would provide important information relating to both biology and potential clinical endpoints. It was hypothesized that FAK activation and complex formation are temporally related in prostate cells, and can thus be separated. Significant activation of FAK was demonstrated when cells adhered to fibronectin, as compared to poly-L-lysine, thus demonstrating that β-1-integrin plays a significant role in activating FAK. Neither FAK activation, nor FAK-integrin complex formation, required β-1-integrin ligand. However, disruption of the cellular cytoskeleton by cytochalasin D prevented FAK activation, but did not block genistein-induced complex formation. In the face of a disrupted cytoskeleton, signaling through FAK could not be restored through either integrin cross linking, or re-establishment of tensile forces via attachment to solid matrix. These studies demonstrate that FAK-β-1-integrin complex formation does not require FAK activation, suggesting that it is an early event in prostate cell adhesion. An intact cytoskeleton is necessary for FAK activation. The functional importance of β-1-integrin in prostate cells is demonstrated. Current findings support plans to test genistein in prostate cancer.

KW - Cell adhesion

KW - Focal adhesion kinase

KW - Genistein

KW - Integrin

KW - Prostate cancer

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0035062953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035062953&partnerID=8YFLogxK

U2 - 10.1023/A:1006729106034

DO - 10.1023/A:1006729106034

M3 - Article

VL - 18

SP - 203

EP - 212

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 3

ER -